We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Advanced Melanoma

Journal Scan / Research · October 19, 2020

Risk Factors for MEK-Associated Retinopathy in Patients With Advanced Melanoma

Therapeutic advances in medical oncology

 

Additional Info

Therapeutic advances in medical oncology
Risk Factors for MEK-Associated Retinopathy in Patients With Advanced Melanoma Treated With Combination BRAF and MEK Inhibitor Therapy
Ther Adv Med Oncol 2020 Jul 31;[EPub Ahead of Print], AEC Booth, AM Hopkins, A Rowland, G Kichenadasse, JR Smith, MJ Sorich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading